近期,香港交易所的IPO申请名单中,生物医药企业的身影显著增多,截至7月9日,今年已有12家生物医药企业成功登陆港交所。医药企业集中赴港上市,其核心背景在于多重因素的共振,包括“18A章”制度红利持续释放、研发管线更多向创新药倾斜企业融资需求更为迫切、港股指数有所提振等等。以君圣泰医药为例,其核心产品HTD1801虽占据主导。但在代谢性疾病领域,GLP-1等靶点早已巨头林立,其未上市便需直面...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.